Search Results

Augmenix, Inc. has opened a new company headquarters, Augmenix KK., in Japan.

Boston Scientific Corporation today announced the close of its acquisition of Augmenix, Inc., a privately-held company that developed and commercialized the SpaceOAR® Hydrogel System to help reduce common and debilitating side effects that men may experience after receiving radiotherapy to treat prostate cancer.

Augmenix, Inc. is pleased to announce that the Geisinger Health Plan and the military payer TRICARE have joined the growing list of insurers now covering the company’s leading product, SpaceOAR hydrogel.

Augmenix is pleased to announce that Aetna, Inc, the third largest commercial health plan provider in the United States.

Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydrogel, which is used in patients receiving radiation therapy for prostate cancer.

Feb. 10, 2020 15:00 UTC ALPHARETTA, Ga.--( BUSINESS WIRE )-- DYSIS Medical today announced that John Pedersen has assumed the position of Board Chairman. Pedersen most recently served as CEO of Augmenix, a privately held company that manufactured and sold minimally invasive hydrogel products to improve outcomes following cancer radiotherapy. Augmenix was sold to Boston Scientific in 2018 for $600M. Prior to joining Augmenix, Pedersen served as a Senior Healthcare Advisor for tw

Acquisition expands portfolio of men’s health in-office procedures with adjunctive therapy for prostate cancer patients